Dual prostacyclin infusions: A case report of a patient symptom–driven transition from high-dose intravenous epoprostenol to subcutaneous treprostinil for the treatment of pulmonary arterial hypertension
This successful transition from high-dose epoprostenol to high-dose subcutaneous treprostinil demonstrates the importance in considering patient-specific factors during high-risk medication transitions, the value of a patient-directed flexible prostacyclin transition plan, and the benefit of institutional training and education in ensuring the safe use of parenteral prostacyclin analogues.
Authors
- Jean Elwing (ORCID: https://orcid.org/0000-0001-6199-1707)
- Arun Jose (ORCID: https://orcid.org/0000-0001-7109-2692)
- Dalton Kuebel (ORCID: https://orcid.org/0000-0002-2782-1322)
- J G Stone
- M. Guido (ORCID: https://orcid.org/0000-0001-9641-3667)
Institutions
- University of Kansas (US)
- University of Colorado Health (US)
- Cincinnati VA Medical Center (US)
- University of Cincinnati (US)
- University of Cincinnati Medical Center (US)
Publication Details
- Journal
- American Journal of Health-System Pharmacy
- Published
- 2024-10-09
- DOI
- https://doi.org/10.1093/ajhp/zxae290
- Citations
- 1
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.42